Figure 8. Pharmacological inhibition of Usp7 improves survival and abrogates lymphoma growth in transplanted Myc-driven B cell lymphomas in vivo.

(A) Kaplan-Meier analysis of C57BL/6 mice with transplanted Eμ-Myc lymphoma cells (clone 1 [Trip13^WT, dashed lines] and clone 2 [Trip13^TG, solid lines]). (B and C) Mice with transplanted Eμ-Myc/Trip13^WT (B) or Eμ-Myc/Trip13^TG (C) lymphoma, treated with vehicle control (black lines), P5091 (10 mg/kg, i.v., twice a week from day 3 after transplant; blue lines), doxorubicin (Doxo; 10 mg/kg, i.p., once on day 7 after transplant; red lines), and combination (green lines) (P values between all groups of each cohort by log-rank test are indicated; n = 6–7 per group). (D and E) Representative flow cytometry plots demonstrating the loss of Eμ-Myc/Trip13^TG donor lymphoma cells (CD45.2⁺CD45.1^–B220⁺IgM^–) after P5091 treatment in CD45.1⁺ recipient mouse lymph node (D) and spleen (E) tumor tissues. Data are represented as mean ± SD. *P < 0.05 by Student’s t test; n = 4 per group.